ArticleCancers2024
Accurate Co-Localization of Luciferase Expression and Fluorescent Anti-CEA Antibody Targeting of Liver Metastases in an Orthotopic Mouse Model of Colon Cancer.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research.Clinical and translational medicine · 2026Pooled it
- Bright Visualization of Primary and Metastatic Medullary Thyroid Cancer in an Orthotopic Nude Mouse Model Using a Fluorescent Humanized Anti-CEA Antibody for More Accurate Staging and Improved Resection.Annals of surgical oncology · 2026Article
- Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles.Npj imaging · 2026Article
- Structure-Activity Relationship of Cyanine Dyes in Relation to the Hepatic Uptake and Excretion.Chembiochem : a European journal of chemical biology · 2026Article
- Fluorescence-guided surgery in colorectal cancer: current evidence, quantitative advances, and future perspectives.Annals of coloproctology · 2026Review
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe present study aimed to validate the accuracy of a tumor-specific antibody to target liver metastases of colorectal cancer.
methodsA humanized anti-CEA antibody conjugated to a fluorescent dye (M5A-IR800) was tested for targeting human colorectal cancer liver metastases (CRLMs) expressing luciferase in an orthotopic mouse model. Orthotopic mouse models of CRLMs were established by implanting fragments of a luciferase-expressing human colorectal cancer cell line, LS174T, in the liver of nude mice. Mice received 50 µg M5A-IR800 72 h prior to imaging. To test co-localization, bioluminescence imaging was performed using D-luciferin, which was given via intraperitoneal injection just prior to imaging.
resultsTumors were able to be visualized non-invasively through the skin with the luciferase-luciferin signal. Intra-abdominal imaging showed accurate labeling of CRLMs with M5A-IR800, which co-localized with the luciferase-luciferin signal.
conclusionsThe present results validate the accuracy of a tumor-specific anti-CEA antibody in targeting liver metastases of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.